// App-Quantinova.ai

2061 : DK049, a novel acid-sensitive prodrug of gemcitabine: design, in vitro properties and in vivo efficacy

Researchers

Presenter

  • David Koester

Principal Investigators

  • Javier Garcia

  • Olga Fuchs

  • Felix Kratz

Medical Centers

  • CytRx Corporation, Freiburg, Germany.

Locations

  • Germany

Companies

  • CytRx Corp.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Human equilibrative nucleoside transporter 1

Drug/Treatment

  • Gemcitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved